Who are Fennec Pharmaceuticals Inc.'s main suppliers?

Fennec Pharmaceuticals Inc. (FENC) key suppliers include: INPHARMUS, NORGINE-PHARMA-UK-LIMITED, ORANY, ORANY. View the full supplier network at chainsifter.com/chain/FENC.

Who are Fennec Pharmaceuticals Inc.'s major customers?

Fennec Pharmaceuticals Inc. (FENC) key customers include: CIPLA-LIMITED, CIPLA-USA-INC, THIRD-PARTY-THAT-ADMINISTERS-THE-COPAY-PROGRAM, ORANY, ORANY and 7 more. View the full customer network at chainsifter.com/chain/FENC.

What sector is Fennec Pharmaceuticals Inc. in?

Fennec Pharmaceuticals Inc. (FENC) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Fennec Pharmaceuticals Inc. Supplier List (FENC): 4 Verified Suppliers

4Suppliers

12Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

Fennec Pharmaceuticals Inc. (FENC) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

20Total relationships

4Distinct source URLs

8High confidence

0.766Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Fennec Pharmaceuticals Inc. Suppliers

Ticker	Name	Confidence	Evidence
INPHARMUS	INPHARMUS	85%	Our strategy depends in part on the efforts of third party development partners to obtain regulatory approvals and commercialize PEDMARK ® outside the United States, including Norgine in Europe and I…
NORGINE-PHARMA-UK-LIMITED	NORGINE-PHARMA-UK-LIMITED	85%	Our strategy depends in part on the efforts of third party development partners to obtain regulatory approvals and commercialize PEDMARK ® outside the United States, including Norgine in Europe
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from FENC graph: y would be the case if we were to manufacture our product. Further, the third parties we deal with could have staffi…
ORANY	ORANY	72%	y would be the case if we were to manufacture our product. Further, the third parties we deal with could have staffing difficulties, might undergo changes in priorities or may become financially dist…

Fennec Pharmaceuticals Inc. Customers

Ticker	Name	Confidence	Evidence
CIPLA-LIMITED	CIPLA-LIMITED	92%	Fennec Pharmaceuticals Inc. entered into a License Agreement with Cipla Limited and Cipla USA, Inc. (together, “Cipla”) to resolve the litigation between the Company and Cipla relating to Cipla’s app…
CIPLA-USA-INC	CIPLA-USA-INC	92%	Fennec Pharmaceuticals Inc. entered into a License Agreement with Cipla Limited and Cipla USA, Inc. (together, “Cipla”) to resolve the litigation between the Company and Cipla relating to Cipla’s app…
THIRD-PARTY-THAT-ADMINISTERS-THE-COPAY-PROGRAM	THIRD-PARTY-THAT-ADMINISTERS-THE-COPAY-PROGRAM	75%	The Company accrues a liability for co-payment assistance based on actual program participation and estimates of program redemption using customer data provided by the third party that administers th…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from FENC graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from FENC graph: Reciprocal relationship from ORAN…
ORANY	ORANY	72%	ained in the Orphan Drug Act has been the subject of recent scrutiny from the press, from some members of Congress and from some in the medical community. Furthermore, the FDA’s interpretations of th…
PCSA	Processa Pharmaceuticals, Inc.	72%	Reciprocal relationship from PCSA graph: Reciprocal relationship from FENC graph: Reciprocal relationship from PCSA graph: Reciprocal relationship from FENC graph: includes stock options and warrants…
PCSA	Processa Pharmaceuticals, Inc.	72%	includes stock options and warrants, if dilutive, as determined using the if-converted method and treasury methods. Reclassifications Certain prior period amounts in the accompanying condensed cons…
ADHEREX-TECHNOLOGIES-INC	ADHEREX-TECHNOLOGIES-INC	62%	merica; and we obtained an understanding of management’s monitoring and oversight of such services. ◾ Through interviews, inquiries, observations, and examination of Company-prepared analyses, we o…
CADHERIN-BIOMEDICAL-INC	CADHERIN-BIOMEDICAL-INC	62%	merica; and we obtained an understanding of management’s monitoring and oversight of such services. ◾ Through interviews, inquiries, observations, and examination of Company-prepared analyses, we o…
HEALTH-RESOURCES	HEALTH-RESOURCES	62%	States Prescription Drug Marketing Act (PDMA), a part of the FDCA. In addition, Title II of the Federal Drug Quality and Security Act of 2013, known as the Drug Supply Chain Security Act (DSCSA), has…
LIQUIDITY-FENNEC-PHARMACEUTICALS-INC	LIQUIDITY-FENNEC-PHARMACEUTICALS-INC	62%	merica; and we obtained an understanding of management’s monitoring and oversight of such services. ◾ Through interviews, inquiries, observations, and examination of Company-prepared analyses, we o…
SEE-FENNEC-PHARMACEUTICALS-INC	SEE-FENNEC-PHARMACEUTICALS-INC	62%	and consistently delivers PEDMARK ® to our customers; ● provide co-pay assistance to help qualified patients with out-of-pocket costs associated with their PEDMARK ® prescription, and/or other progra…

Fennec Pharmaceuticals Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
FENC-DEBT-9472	Warrants outstanding: 8	90%	xbrl warrant detail from xbrl 2025-09-30.
FENC-DEBT	Debt stack $26.0M	90%	Market cache reports total debt of $26.0M.
FENC-DEBT-9473	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2013-12-31.

Fennec Pharmaceuticals Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Fennec Pharmaceuticals Inc..

Fennec Pharmaceuticals Inc. Ownership

Holder	Name	Confidence	Evidence
FENC-OWNER-ROSALIND-ADVISORS-INC	Rosalind Advisors, Inc.	90%	13F overlay lists Rosalind Advisors, Inc. as top holder; 91 tracked holders.

Fennec Pharmaceuticals Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
ORANY	ORANGE	100.00	1	['customer', 'supplier']
AMZE	Amaze Holdings, Inc.	50.00	2
ESS	Essex Property Trust, Inc.	50.00	2
AYTU	Aytu BioPharma, Inc.	50.00	2
CYCN	Cyclerion Therapeutics, Inc.	50.00	2
D	Dominion Energy, Inc.	50.00	2
DARE	Daré Bioscience, Inc.	50.00	2
CANF	Can-Fite BioPharma Ltd.	50.00	2
DFTX	Definium Therapeutics, Inc.	50.00	2
CHUC	Charlie's Holdings, Inc.	50.00	2
CLNE	Clean Energy Fuels Corp.	50.00	2
EQR	Equity Residential	50.00	2
CNOB	ConnectOne Bancorp, Inc.	50.00	2
DWTX	Dogwood Therapeutics, Inc.	50.00	2
CPRX	Catalyst Pharmaceuticals, Inc.	50.00	2
ED	Consolidated Edison, Inc.	50.00	2
CORT	Corcept Therapeutics Incorporated	50.00	2
BSBK	Bogota Financial Corp.	50.00	2
FCFS	FirstCash Holdings, Inc.	50.00	2
BLTE	Belite Bio, Inc	50.00	2

Fennec Pharmaceuticals Inc. Supply Chain